Observational Study for Patients with LAMA2 Aged 0-5 years old

Phase: Recruiting

First Posted: March

Condition(s): LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)

Other Study ID Number(s): Ready CMD LAMA2

What Is the Purpose of This Study?

The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems.

Who Can Take Part in This Study?

  • Patient aged birth to less than 5.0 years of age at time of consent.
  • A confirmed diagnosis of LAMA2-RD confirmed via:
    • Two pathogenic variants in the LAMA2 gene (via a CLIA-approved laboratory)
    • Muscle biopsy with absence of merosin (laminin-211) and at least one pathogenic variant in the LAMA2 gene
  • Absence of another confirmed genetic disease.
  • Willingness to maintain current exercise and/or physical therapy regimen for the duration of the clinical study.
  • Willingness to comply with the study protocol, including but not limited to, all study procedures and visits.

For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT06503367

What Will Happen During This Study?

  • The total duration for each participant is up to 24 months
  • In-clinic visits at baseline, month 6, month 12, month 18 and month 24
  • Neuromuscular assessments
  • Blood collections
  • Swallowing and breathing assessments
  • Questionnaires

Principal Investigator

Anne M. Connolly
MD

Neurology

Discover More Research
Explore additional studies relating to gene therapy